CS Paper Radar

AbGaze: Attentive Geometric Representation Learning for End-to-End Antibody Design

Jiashuo Wang, Siqi Fan, Yizhen Luo, Zaiqing Nie

cs.AI ·submitted 2026-09-28 14:38 UTC · v1

Abstract

Computational antibody design requires representations that capture the geometric patterns underlying antigen--antibody interactions, yet existing approaches often rely on scalar distances or surface-intrinsic features, leaving cross-molecular geometry largely implicit. We present AbGaze, an end-to-end antibody design framework based on attentive geometric representation learning, which encodes distance, spatial direction, and surface-normal orientation of antigen surfaces relative to antibody-residue local frames, and adaptively aggregates these geometric interactions according to their interfacial context. The learned interaction representation is shared across multi-CDR co-design, complex structure prediction, and affinity optimization, with local-frame geometric supervision further constraining the representation. AbGaze outperforms prior methods across all three tasks: relative to the second-best method, it improves amino-acid recovery by 7.1% and reduces structural error by 14.9% on average over the six CDRs, improves interface docking quality (DockQ) by 6.6%, and raises the affinity improvement rate (IMP) by 32.5%.

Closest papers

Nearest neighbours by meaning across the whole index.

From Surfaces to Volumes: Registered Geometry for Protein Representation Learning

cs.AI ·2026-09-28 ·Siyuan Chen, Cai Zhou, Jinrui Zhang, Zhaokang Liang, Taku Komura +6 more
similarity 0.61
Abstract

Existing protein geometry models typically represent molecular surfaces using local geometric features such as sampled points, normals, and curvature. While effective for capturing exposed molecular shape, these representations do not explicitly model the volumetric organization beneath the surface or provide a consistent coordinate system for residue-wise volumetric structure. We introduce Protein-TetSphere, a registered residue-wise volumetric representation for proteins. Each protein chain is tetrahedralized to obtain local volumetric regions associated with individual residues, which are then registered to a shared fixed-topology tetrahedral reference and represented in a common Laplacian basis. This registration establishes consistent volumetric coordinates across residues, enabling local three-dimensional deformation to be integrated with surface and chemical information in a multimodal protein representation. We evaluate Protein-TetSphere on ligand-binding pocket classification, protein--protein interface prediction, and de novo protein binder design. Across the three tasks, Protein-TetSphere improves ligand-binding pocket balanced accuracy from $0.795$ to $0.826$, Pinder-Pair/Site AUROC from $0.914/0.852$ to $0.932/0.866$, and binder-design success from $14.95\%$ to $19.90\%$ on the BoltzGen Challenge Set and from $27.62\%$ to $32.19\%$ at the ProtDBench backbone level. These results show that registered volumetric geometry provides complementary spatial information beyond molecular surfaces across protein recognition, interaction, and design.

0.18

Revisiting Structure-Based Filtering for AI-Designed Antibodies: Opportunities, Limits, and What Matters

cs.CE ·2026-10-16 ·Langzhang Liang, Juncheng Qian, Xiaojie Ma, Mingxi Zou, Yinghui Xu +2 more
similarity 0.60
Abstract · 29 pages, 4 figures

AI antibody design can generate far more candidates than can be experimentally tested, making post-generation filtering a central bottleneck. We study whether structure-prediction outputs can help prioritize AI-designed antibodies for experimental validation. We evaluate this problem on 4,184 experimentally characterized antibody-antigen pairs, combining newly generated wet-lab measurements with curated affinity data across diverse antigens and assay settings. We introduce two complementary filtering signals: Regional Interaction Contrast (RIC), which captures support for the predicted antibody-antigen interface, and Non-CDR Antibody Confidence (NAC), which measures antibody confidence outside the CDRs. Across AlphaFold 3, Protenix-v2, and ESMFold2, we find a striking difference in what information matters for filtering. Interface evidence is strongest when comparing candidates designed for different antigens, whereas antibody-level reliability is substantially more informative for ranking candidates within the same antigen. In particular, non-CDR antibody confidence consistently outperforms whole-antibody confidence across predictors, revealing an unexpected source of filtering signal beyond the predicted interface. Finally, we examine the information encoded in the predictor outputs themselves. Predicted structures contain substantial but incomplete binding-related signal, revealing both the opportunities and limits of structure-based filtering: better metrics can exploit current predictors more effectively, but their performance ultimately remains constrained by what those predictors can distinguish.

0.32

Multi-Assay Antibody Developability Prediction with Shared Structure-Language Representations

cs.LG q-bio.BM ·2026-11-13 ·Daria B. Kokh
similarity 0.59
Abstract · 27 pages, 11 figures, 4 tables, Supplementary Material

Early assessment of antibody developability is critical in drug discovery, but computational approaches remain limited by the scarcity of experimental data. We explore two strategies for working within that limit. First, we designed per-residue physicochemical descriptors encoding the local structural environment, including new terms such as directional charge asymmetry and screened electrostatic potential. These feed a convolutional network, combined with protein language model (PLM) embeddings in a two-stream architecture: the two are encoded and predicted independently and merged only at the prediction stage. Second, a shared trunk with per-assay heads passes information between related assays. Both are implemented in the Multi-Assay Developability Model (MADM) and evaluated on eight assays: HIC, heparin affinity (HAC), AC-SINS, and polyspecificity ELISA against BVP, dsDNA, insulin, ovalbumin and soluble membrane proteins (SMP), with labels from 29 open sources. Structural descriptors match or exceed PLM embeddings (AbLang2, ESM2) on several assays; combining the streams gives a small but consistent gain in accuracy and reduces seed-to-seed variance. Multi-assay training raises Spearman rho for ovalbumin and SMP by about 0.1, where assays correlate and share sequence space. Under cluster-split cross-validation the strongest results are for HAC, ovalbumin, insulin, SMP and HIC (rho = 0.70-0.82); AC-SINS, BVP and dsDNA are weaker (0.50-0.55). In these three, sequence clusters largely coincide with data source, so a held-out fold measures transfer to differently calibrated measurements as well as to new sequences. On the 80-antibody GDPa3 hold-out, performance falls by rho around 0.1 for all but SMP (0.22). Transfer to the VHH panel of Ginkgo GDPa5 gives comparable results, and scFv validation against binary SMP labels yields F1 = 0.89, AUC = 0.95.

0.29

Joint Discrete and SE(3) Diffusion for Protein Interface Design

cs.AI ·2026-10-10 ·Zhenqiao Song, Jianwen Xie, Lei Li
similarity 0.58
Abstract

The design of high-affinity, target-specific protein binders is central to the development of modern therapeutics. However, existing protein-generation methods remain limited in this setting, as many generated designs fail to simultaneously achieve geometric and physicochemical complementarity at binding interfaces. To address this challenge, we introduce PIDiff, a physicochemically enhanced multimodal diffusion framework for protein-protein complex design. PIDiff jointly designs target-conditioned protein sequences and structures by coupling diffusion in discrete sequence space with diffusion on the continuous (SE(3)) structural manifold. At its core, PIDiff employs PIFormer, a novel architecture that interleaves geometry-aware invariant point attention with global sequence self-attention. We further curate PIBench, a protein-protein complex dataset with diverse target scaffolds derived from the Protein Data Bank (PDB). We first pretrain PIDiff on PIBench and subsequently fine-tune it for two therapeutically relevant applications: minibinder design and antibody design. PPFrame consistently outperforms baseline methods across sequence design success rate, structure binding energy, and sequence-structure co-designability on all tasks.

0.15

Chemical and geometric representation fidelity improves drug--target affinity prediction

cs.AI q-bio.BMcs.LGstat.ML ·2026-09-02 ·Yixiao Li, Yining Qian, Yefan Chen, Zenghui Chen, Jiayue Sun +3 more
benchmark similarity 0.58
Abstract · 21 pages, 10 figures

Predicting drug--target binding affinity (DTA) requires models to distinguish subtle chemical and structural determinants underlying molecular recognition. Although recent approaches increasingly incorporate richer drug and protein information, such information may be compressed, homogenized or discretized during representation construction, causing affinity-relevant distinctions to be lost before interaction modelling. We hypothesized that this representation-stage information loss constitutes an upstream bottleneck that cannot be reliably overcome by increasingly complex interaction predictors. To test this hypothesis, we developed ReGeoDTA, a representation-preserving framework that maintains affinity-relevant chemical heterogeneity in molecular representations and continuous geometric relationships in protein structures. Across three benchmark datasets, ReGeoDTA consistently improved affinity prediction, and the proposed representation-preserving strategies retained their benefits across diverse DTA architectures. Controlled representation degradation progressively reduced predictive performance, whereas increasing downstream predictor complexity failed to recover information lost during representation construction. These findings identify representation fidelity as an upstream design principle for accurate and generalizable drug--target affinity prediction, with potential implications for computational compound prioritization.

0.23

PIT-GCL: Protein Interaction using Topological Graph Contrastive Learning

cs.LG cs.AI ·2026-10-04 ·Jae Won Choi, Ryoonki Hong, Alan Liang, Manjula Adiveppa Wader, Bingsong Zeng +3 more
similarity 0.57
Abstract · 12pages, 6figures

Protein binding prediction is central to target identification, therapeutic binder design, and large scale screening, yet remains challenging because binding depends on sequence, three dimensional geometry, and global structural organization. Recent folding models such as AlphaFold3 and Boltz-2 have substantially improved structure prediction, but their confidence outputs (pLDDT, pTM, ipTM) are not specifically designed for binary binding prediction, and dedicated structure aware predictors often require bound complex structures that are unavailable at screening scale. We introduce PIT-GCL, a dual tower structure aware framework that encodes each protein independently from its amino acid sequence, Cα point cloud, and a global persistent homology descriptor. Each tower combines residue ESM-2 embeddings with a topological summary computed from the H0 and H1 persistence landscapes of a Vietoris-Rips filtration, and processes the resulting tokens with a structure aware Transformer in which pairwise Cα distances enter as a learned attention bias. A bidirectional cross attention module then performs latent space soft docking between the two per-protein representations, and the model is trained with a combined binary cross entropy and NT-Xent contrastive objective. On three binary interaction prediction benchmarks, general PPI on PPIRef, TCRpMHC binding on STAG, and whole chain pairs on PPB-Affinity, PIT-GCL outperforms representative sequence based, structure aware, and task specific baselines on general PPI under our evaluation, and is the only method above chance on PPB-Affinity; on TCR-pMHC it leads at a fixed decision threshold but is outranked by a task specific sequence model. Because each protein is encoded independently in the first phase, its representation can be precomputed and reused across candidate pairs, which is convenient for large scale screening.

0.25

Learning Task-Specific Antibody Representations via Function-Aware Masking

cs.LG q-bio.BM ·2026-09-01 ·Ayan Goel, Thomas A. Walton, Amirali Aghazadeh
published similarity 0.57
Abstract · Accepted to MLCB 2026 (Oral)

Antibody-specific language models pretrained via masked language modeling (MLM) learn representations that are critical for downstream sequence design and property prediction tasks. Yet, the corruption process itself is rarely leveraged as a source of inductive bias during pretraining. While preferentially masking complementarity-determining regions (CDRs) improves binding-related predictions, antibodies possess diverse biological priors over a variety of functions. Herein, we introduce function-aware masking, a family of pretraining algorithms that align mask placement with specific functional priors (e.g., from IMGT annotations or structure predictions) to shape the learned representation space. We show that these specialist masking strategies significantly improve performance on their respective objectives, yielding up to a 14% gain on structure-related tasks and up to a 5.9x improvement on CDR-related tasks. To further improve performance across multiple functional axes, we develop hybrid masking strategies that integrate multiple priors, balancing reconstruction over binding, structural, and biophysical objectives. Our results demonstrate that informed mask placement provides a parameter-free mechanism for imposing functional inductive biases in antibody language model training.

0.31

Multi-Objective Amortized CDRH3 Sequence Sampling Diversifies Promising Antibody Candidates

cs.CE ·2026-10-12 ·Joseph D. Viviano, Almer van der Sloot, Quentin Fournier, Robert M. Vernon, Christopher James Langmead +1 more
similarity 0.56
Abstract · 21 Figures, 14 Tables, Under review

Antibody therapeutics have transformed treatment across diverse therapeutic areas and have become central to modern medicine. While recent machine learning approaches aim to accelerate antibody discovery through structure-based design and target-affinity optimization, successful candidates must also satisfy broad developability constraints, including structural compatibility, low immunogenicity, and favorable biophysical properties, while remaining sufficiently diverse to provide sufficient coverage of design space to mitigate later-stage development failures. We introduce a preference-conditioned multi-objective generative flow network (GFN) fine-tuning pipeline for fixed-framework CDRH3 loop redesign that fine-tunes a biological sequence model against many inexpensive proxies covering backbone compatibility, sequence likelihood, immunogenicity risk, novelty, and developability liabilities. It combines up to fourteen predictive rewards in a single policy trained to sample CDRH3 loops across 623 SAbDab antibody structures, leveraging a reward reduction strategy to preserve Pareto dominance under this learned map. We also introduce a novel autoregressive span-in-filling variant of AMPLIFY-350M that serves both as a scaffold-conditioned CDRH3 generation prior and as a direct conditional likelihood scorer. We evaluated reward scores, diversity, and design quality on loops sampled on 45 held-out antibody complexes to assess structural consistency, confidence, aggregation propensity, stability, and antigen binding. Compared with the inverse-folding methods ProteinMPNN and ESM-IF, our approach produces roughly 10x more distinct acceptable candidates per design at 50% sequence identity, while holding 10% of the 14-objective Pareto front pooled across methods, trading per-sample quality for greater exploration of novel possible structures.

0.33